Pharmaceutical Press Releases - Bristol-Myers Squibb

Read current and archived press releases.

30/05/23

Bringing Patient Centricity to Life

02/11/22

Bristol Myers Squibb Australia has been named on the 2022 Best Workplaces for Women List

24/10/22

New leadership for BMS Australia and New Zealand

04/10/22

First treatment in 10 years PBS listed for Aussies living with aggressive stomach & oesophageal cancers

04/10/21

National Medicines Policy – BMS response

22/06/21

New treatment for Aussies living with asbestos-related cancer

28/02/21

New treatment for most common form of MS now available on PBS

31/05/20

New combination therapy now reimbursed for Australians living with incurable blood cancer

31/03/20

Australians living with an incurable blood cancer set to receive new reimbursed treatment option

31/08/19

Four weekly dosing of immuno-oncology treatment for cancer patients available on the PBS from 1st September 2019

28/02/19

Combination immuno-oncology treatment for Kidney Cancer patients available on the PBS from 1st March 2019

29/11/18

First combination immuno-oncology treatment available on pharmaceutical benefits scheme from 1st December

15/10/18

New leader for Bristol Myers Squibb in Australia and New Zealand

25/09/18

First Combination Immunotherapy for Advanced Kidney Cancer Approved for use in Australia

26/07/18

Media Release: OPDIVO now PBS listed for treatment of advanced head and neck cancer (consumer version)

20/06/18

OPDIVO now TGA approved for adjuvant treatment of advanced melanoma (consumer version)

24/07/17

NSCLC PBS listing (consumer version)

24/07/17

RCC PBS listing (consumer)

01/05/17

Bristol Myers Squibb Australia supports The Bridge Program.

23/11/16

OPDIVO (nivolumab) approved for advanced kidney cancer.

02/11/16

New BMS patient resource; a guide to immuno-oncology.

30/04/16

OPDIVO (nivolumab) listed on the PBS for the treatment of advanced melanoma.

28/03/16

New BMS guides published about access to medicines in Australia.

17/03/16

OPDIVO (nivolumab) approved for advanced non squamous non-small cell lung cancer.

29/02/16

Daklinza (daclatasvir) listed on the PBS for chronic hepatitis C.

30/01/16

Immuno-oncology agent Opdivo (nivolumab) approved for advanced melanoma & lung cancer.

08/06/15

BMS Australia – Best employer 3rd year running.

Read Bristol Myers Squibb’s Stories About Life & Science >